Melatonin as a treatment for gastrointestinal cancer: A review

Journal of Pineal Research

Volumn 58, Issue 4, 2015, Pages 375-387

  Xin, Zhenlong ^a,b   Jiang, Shuai ^b   Jiang, Peng ^c   Yan, Xiaolong ^d   Fan, Chongxi ^d   Di, Shouyin ^d   Wu, Guiling ^b   Yang, Yang ^a,b   Reiter, Russel J ^e   Ji, Gang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c Hospital of PLA   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

drug synergy; gastrointestinal cancer; melatonin; melatonin receptors

Indexed keywords

ANTINEOPLASTIC AGENT; MELATONIN; MELATONIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; AWARENESS; CANCER INCIDENCE; CANCER PATIENT; CARCINOGENESIS; CELL PROLIFERATION; DIGESTIVE SYSTEM CANCER; DRUG POTENTIATION; EPIDEMIOLOGY; HORMONE SYNTHESIS; HUMAN; METASTASIS; NONHUMAN; REVIEW; TUMOR IMMUNITY; TUMOR INVASION; ANIMAL; DRUG EFFECTS; GASTROINTESTINAL NEOPLASMS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC;

ANIMALS; CELL PROLIFERATION; DRUG SYNERGISM; GASTROINTESTINAL NEOPLASMS; HUMANS; MELATONIN; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, MELATONIN;

EID: 84926466801     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12227     Document Type: Review

References (128)

1. Nasrabadi NN, Ataee R, Abediankenari S, et al. Expression of MT2 receptor in patients with gastric adenocarcinoma and its relationship with clinicopathological features. J Gastrointest Cancer 2014; 45: 54-60.
2. Bozkurt O, Inanc M, Turkmen E, et al. Clinicopathological characteristics and prognosis of patients according to recurrence time after curative resection for colorectal cancer. Asian Pac J Cancer Prev 2014; 15: 9277-9281.
3. Sanchez-Hidalgo M, Guerrero JM, Villegas I, et al. Melatonin, a natural programmed cell death inducer in cancer. Curr Med Chem 2012; 19: 3805-3821.
4. Walczak K, Deneka-Hannemann S, Jarosz B, et al. Kynurenic acid inhibits proliferation and migration of human glioblastoma T98G cells. Pharmacol Rep 2014; 66: 130-136.
5. Walczak K, Zurawska M, Kis J, et al. Kynurenic acid in human renal cell carcinoma: its antiproliferative and antimigrative action on Caki-2 cells. Amino Acids 2012; 43: 1663-1670.
6. Walczak K, Turski WA, Rajtar G,. Kynurenic acid inhibits colon cancer proliferation in vitro: effects on signaling pathways. Amino Acids 2014; 46: 2393-2401.
7. Walczak K, Turski WA, Rzeski W,. Kynurenic acid enhances expression of p21 Waf1/Cip1 in colon cancer HT-29 cells. Pharmacol Rep 2012; 64: 745-750.
8. Xu L, Liu H, Zhang H, et al. Growth-inhibitory activity of melatonin on murine foregastric carcinoma cells in vitro and the underlying molecular mechanism. Anat Rec (Hoboken) 2013; 296: 914-920.
9. Zhang S, Qi Y, Zhang H, et al. Melatonin inhibits cell growth and migration, but promotes apoptosis in gastric cancer cell line, SGC7901. Biotech Histochem 2013; 88: 281-289.
10. Kannen V, Marini T, Zanette DL, et al. The melatonin action on stromal stem cells within pericryptal area in colon cancer model under constant light. Biochem Biophys Res Commun 2011; 405: 593-598.
11. Wang J, Guo W, Chen W, et al. Melatonin potentiates the antiproliferative and pro-apoptotic effects of ursolic acid in colon cancer cells by modulating multiple signaling pathways. J Pineal Res 2013; 54: 406-416.
12. Alvarez-Garcia V, Gonzalez A, Alonso-Gonzalez C, et al. Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells. J Pineal Res 2013; 54: 373-380.
13. Blask DE, Dauchy RT, Dauchy EM, et al. Light exposure at night disrupts host/cancer circadian regulatory dynamics: impact on the Warburg effect, lipid signaling and tumor growth prevention. PLoS ONE 2014; 9: e102776.
14. Cos S, Alvarez-Garcia V, Gonzalez A, et al. Melatonin modulation of crosstalk among malignant epithelial, endothelial and adipose cells in breast cancer (Review). Oncol Lett 2014; 8: 487-492.
15. Proietti S, Cucina A, Dobrowolny G, et al. Melatonin down-regulates MDM2 gene expression and enhances p53 acetylation in MCF-7 cells. J Pineal Res 2014; 57: 120-129.
16. Rodriguez-Garcia A, Mayo JC, Hevia D, et al. Phenotypic changes caused by melatonin increased sensitivity of prostate cancer cells to cytokine-induced apoptosis. J Pineal Res 2013; 54: 33-45.
17. Shiu SY, Leung WY, Tam CW, et al. Melatonin MT1 receptor-induced transcriptional up-regulation of p27(Kip1) in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NF-kappaB): potential implications on prostate cancer chemoprevention and therapy. J Pineal Res 2013; 54: 69-79.
18. Paroni R, Terraneo L, Bonomini F, et al. Antitumour activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signalling. J Pineal Res 2014; 57: 43-52.
19. Cutando A, Lopez-Valverde A, De Vicente J, et al. Action of melatonin on squamous cell carcinoma and other tumors of the oral cavity (Review). Oncol Lett 2014; 7: 923-926.
20. Goncalves Ndo N, Rodrigues RV, Jardim-Perassi BV, et al. Molecular markers of angiogenesis and metastasis in lines of oral carcinoma after treatment with melatonin. Anticancer Agents Med Chem 2014; 14: 1302-1311.
21. Leja-Szpak A, Jaworek J, Pierzchalski P, et al. Melatonin induces pro-apoptotic signaling pathway in human pancreatic carcinoma cells (PANC-1). J Pineal Res 2010; 49: 248-255.
22. Jaworek J, Leja-Szpak A,. Melatonin influences pancreatic cancerogenesis. Histol Histopathol 2014; 29: 423-431.
23. Xu C, Wu A, Zhu H, et al. Melatonin is involved in the apoptosis and necrosis of pancreatic cancer cell line SW-1990 via modulating of Bcl-2/Bax balance. Biomed Pharmacother 2013; 67: 133-139.
24. Carbajo-Pescador S, Ordonez R, Benet M, et al. Inhibition of VEGF expression through blockade of Hif1alpha and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br J Cancer 2013; 109: 83-91.
25. Fan L, Sun G, Ma T, et al. Melatonin overcomes apoptosis resistance in human hepatocellular carcinoma by targeting survivin and XIAP. J Pineal Res 2013; 55: 174-183.
26. Fan L, Sun G, Ma T, et al. Melatonin reverses tunicamycin-induced endoplasmic reticulum stress in human hepatocellular carcinoma cells and improves cytotoxic response to doxorubicin by increasing CHOP and decreasing survivin. J Pineal Res 2013; 55: 184-194.
27. Ordonez R, Carbajo-Pescador S, Prieto-Dominguez N, et al. Inhibition of matrix metalloproteinase-9 and nuclear factor kappa B contribute to melatonin prevention of motility and invasiveness in HepG2 liver cancer cells. J Pineal Res 2014; 56: 20-30.
28. Acuna-Castroviejo D, Escames G, Venegas C, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci 2014; 71: 2997-3025.
29. Bubenik GA,. Thirty four years since the discovery of gastrointestinal melatonin. J Physiol Pharmacol 2008; 59 (Suppl. 2): 33-51.
30. Bubenik GA,. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci 2002; 47: 2336-2348.
31. Kolli VK, Kanakasabapathy I, Faith M, et al. A preclinical study on the protective effect of melatonin against methotrexate-induced small intestinal damage: effect mediated by attenuation of nitrosative stress, protein tyrosine nitration, and PARP activation. Cancer Chemother Pharmacol 2013; 71: 1209-1218.
32. Lissoni P,. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol Biol (Paris) 2007; 55: 201-204.
33. Tanaka T, Yasui Y, Tanaka M, et al. Melatonin suppresses AOM/DSS-induced large bowel oncogenesis in rats. Chem Biol Interact 2009; 177: 128-136.
34. Arabski M, Kazmierczak P, Wisniewska-Jarosinska M, et al. Helicobacter pylori infection can modulate the susceptibility of gastric mucosa cells to MNNG. Cell Mol Biol Lett 2006; 11: 570-578.
35. Leon J, Casado J, Jimenez Ruiz SM, et al. Melatonin reduces endothelin-1 expression and secretion in colon cancer cells through the inactivation of FoxO-1 and NF-kappabeta. J Pineal Res 2014; 56: 415-426.
36. Parent ME, El-Zein M, Rousseau MC, et al. Night work and the risk of cancer among men. Am J Epidemiol 2012; 176: 751-759.
37. Anisimov VN, Baturin DA, Popovich IG, et al. Effect of exposure to light-at-night on life span and spontaneous carcinogenesis in female CBA mice. Int J Cancer 2004; 111: 475-479.
38. Lewy AJ, Wehr TA, Goodwin FK, et al. Light suppresses melatonin secretion in humans. Science 1980; 210: 1267-1269.
39. Brainard GC, Richardson BA, King TS, et al. The suppression of pineal melatonin content and N-acetyltransferase activity by different light irradiances in the Syrian hamster: a dose-response relationship. Endocrinology 1983; 113: 293-296.
40. Reiter RJ, Tan DX, Korkmaz A, et al. Light at night, chronodisruption, melatonin suppression, and cancer risk: a review. Crit Rev Oncog 2007; 13: 303-328.
41. Pechanova O, Paulis L, Simko F,. Peripheral and central effects of melatonin on blood pressure regulation. Int J Mol Sci 2014; 15: 17920-17937.
42. Anisimov VN, Vinogradova IA, Panchenko AV, et al. Light-at-night-induced circadian disruption, cancer and aging. Curr Aging Sci 2012; 5: 170-177.
43. Anisimov VN,. Light pollution, reproductive function and cancer risk. Neuro Endocrinol Lett 2006; 27: 35-52.
44. Papantoniou K, Kogevinas M, Martin Sanchez V, et al. 0058 Colorectal cancer risk and shift work in a population-based case-control study in Spain (MCC-Spain). Occup Environ Med 2014; 71 (Suppl. 1): A5-A6.
45. Vineis P, Schatzkin A, Potter JD,. Models of carcinogenesis: an overview. Carcinogenesis 2010; 31: 1703-1709.
46. Anderl F, Gerhard M,. Helicobacter pylori vaccination: is there a path to protection? World J Gastroenterol 2014; 20: 11939-11949.
47. Hayashi S, Hamada T, Zaidi SF, et al. Nicotine suppresses acute colitis and colonic tumorigenesis associated with chronic colitis in mice. Am J Physiol Gastrointest Liver Physiol 2014; 307: G968-G978.
48. Lu L, Chan RL, Luo XM, et al. Animal models of gastrointestinal inflammation and cancer. Life Sci 2014; 108: 1-6.
49. Konturek PC, Konturek SJ, Celinski K, et al. Role of melatonin in mucosal gastroprotection against aspirin-induced gastric lesions in humans. J Pineal Res 2010; 48: 318-323.
50. Brzozowski T, Jaworek J,. Editorial: basic and clinical aspects of melatonin in the gastrointestinal tract. New advancements and future perspectives. Curr Pharm Des 2014; 20: 4785-4787.
51. Russo F, Linsalata M, Orlando A,. Probiotics against neoplastic transformation of gastric mucosa: effects on cell proliferation and polyamine metabolism. World J Gastroenterol 2014; 20: 13258-13272.
52. Pluchino LA, Wang HC,. Chronic exposure to combined carcinogens enhances breast cell carcinogenesis with mesenchymal and stem-like cell properties. PLoS ONE 2014; 9: e108698.
53. Poplawski T, Chojnacki C, Czubatka A, et al. Helicobacter pylori infection and antioxidants can modulate the genotoxic effects of heterocyclic amines in gastric mucosa cells. Mol Biol Rep 2013; 40: 5205-5212.
54. Arabski M, Kazmierczak P, Wisniewska-Jarosinska M, et al. Interaction of amoxicillin with DNA in human lymphocytes and H. pylori-infected and non-infected gastric mucosa cells. Chem Biol Interact 2005; 152: 13-24.
55. Liu R, Fu A, Hoffman AE, et al. Melatonin enhances DNA repair capacity possibly by affecting genes involved in DNA damage responsive pathways. BMC Cell Biol 2013; 14: 1.
56. Winczyk K, Pawlikowski M, Guerrero JM, et al. Possible involvement of the nuclear RZR/ROR-alpha receptor in the antitumor action of melatonin on murine Colon 38 cancer. Tumour Biol 2002; 23: 298-302.
57. Anisimov VN, Popovich IG, Shtylik AV, et al. Melatonin and colon carcinogenesis. III. Effect of melatonin on proliferative activity and apoptosis in colon mucosa and colon tumors induced by 1,2-dimethylhydrazine in rats. Exp Toxicol Pathol 2000; 52: 71-76.
58. Riabykh TP, Nikolaeva TG, Bodrova NB,. Effects of biorhythm regulator melatonin on DNA synthesis in short-term cultures of human malignant tumors. Vestn Ross Akad Med Nauk 2000; 8: 30-33.
59. Farriol M, Venereo Y, Orta X, et al. In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line. J Appl Toxicol 2000; 20: 21-24.
60. Tan J, Yang X, Jiang X, et al. Integrative epigenome analysis identifies a Polycomb-targeted differentiation program as a tumor-suppressor event epigenetically inactivated in colorectal cancer. Cell Death Dis 2014; 5: e1324.
61. Bonhin RG, de Carvalho GM, Guimaraes AC, et al. Histologic correlation of expression of Ki-67 in squamous cell carcinoma of the glottis according to the degree of cell differentiation. Braz J Otorhinolaryngol 2014; 80: 290-295.
62. Anisimov VN, Popovich IG, Zabezhinski MA,. Melatonin and colon carcinogenesis: I. Inhibitory effect of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats. Carcinogenesis 1997; 18: 1549-1553.
63. Zhang S, Zuo L, Gui S, et al. Induction of cell differentiation and promotion of endocan gene expression in stomach cancer by melatonin. Mol Biol Rep 2012; 39: 2843-2849.
64. Kiedrowski M, Mroz A,. The effects of selected drugs and dietary compounds on proliferation and apoptosis in colorectal carcinoma. Contemp Oncol (Pozn) 2014; 18: 222-226.
65. Chen S, Zhao Y, Zhang Y, et al. Fucoidan induces cancer cell apoptosis by modulating the endoplasmic reticulum stress cascades. PLoS ONE 2014; 9: e108157.
66. Bizzarri M, Proietti S, Cucina A, et al. Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review. Expert Opin Ther Targets 2013; 17: 1483-1496.
67. Li YL, Yang TS, Ruan WM, et al. Effect of trichostatin a on SGC-7901 gastric cancer cells. Int J Clin Exp Med 2014; 7: 1958-1966.
68. Batista AP, da Silva TG, Teixeira AA, et al. Ultrastructural aspects of melatonin cytotoxicity on Caco-2 cells in vitro. Micron 2014; 59: 17-23.
69. Hong Y, Won J, Lee Y, et al. Melatonin treatment induces interplay of apoptosis, autophagy, and senescence in human colorectal cancer cells. J Pineal Res 2014; 56: 264-274.
70. Liu H, Xu L, Wei JE, et al. Role of CD4+ CD25+ regulatory T cells in melatonin-mediated inhibition of murine gastric cancer cell growth in vivo and in vitro. Anat Rec (Hoboken) 2011; 294: 781-788.
71. Thakur RK, Yadav VK, Kumar A, et al. Non-metastatic 2 (NME2)-mediated suppression of lung cancer metastasis involves transcriptional regulation of key cell adhesion factor vinculin. Nucleic Acids Res 2014; 42: 11589-11600.
72. Merino D, Best SA, Asselin-Labat ML, et al. Pro-apoptotic Bim suppresses breast tumor cell metastasis and is a target gene of SNAI2. Oncogene 2014; doi: 10.1038/onc.2014.313. [Epub ahead of print]
73. Kim SD, Lee YJ, Baik JS, et al. Baicalein inhibits agonist- and tumor cell-induced platelet aggregation while suppressing pulmonary tumor metastasis via cAMP-mediated VASP phosphorylation along with impaired MAPKs and PI3K-Akt activation. Biochem Pharmacol 2014; 92: 251-265.
74. Swarnakar S, Paul S, Singh LP, et al. Matrix metalloproteinases in health and disease: regulation by melatonin. J Pineal Res 2011; 50: 8-20.
75. Hwang TL, Changchien TT, Wang CC, et al. Claudin-4 expression in gastric cancer cells enhances the invasion and is associated with the increased level of matrix metalloproteinase-2 and -9 expression. Oncol Lett 2014; 8: 1367-1371.
76. Talero E, Garcia-Maurino S, Motilva V,. Melatonin, autophagy and intestinal bowel disease. Curr Pharm Des 2014; 20: 4816-4827.
77. Rudra DS, Pal U, Maiti NC, et al. Melatonin inhibits matrix metalloproteinase-9 activity by binding to its active site. J Pineal Res 2013; 54: 398-405.
78. Wang T, Liu G, Wang R,. The intercellular metabolic interplay between tumor and immune cells. Front Immunol 2014; 5: 358.
79. Pais I, Correia N, Pimentel I, et al. Effects of acupuncture on leucopenia, neutropenia, NK, and B cells in cancer patients: a randomized pilot study. Evid Based Complement Alternat Med 2014; 2014: 217397.
80. Toso A, Revandkar A, Di Mitri D, et al. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Rep 2014; 9: 75-89.
81. Dong B, Minze LJ, Xue W, et al. Molecular insights into the development of T cell-based immunotherapy for prostate cancer. Expert Rev Clin Immunol 2014; 10: 1547-1557.
82. Carrillo-Vico A, Guerrero JM, Lardone PJ, et al. A review of the multiple actions of melatonin on the immune system. Endocrine 2005; 27: 189-200.
83. Calvo JR, Gonzalez-Yanes C, Maldonado MD,. The role of melatonin in the cells of the innate immunity: a review. J Pineal Res 2013; 55: 103-120.
84. Srinivasan V, Pandi-Perumal SR, Brzezinski A, et al. Melatonin, immune function and cancer. Recent Pat Endocr Metab Immune Drug Discov 2011; 5: 109-123.
85. Bubenik GA, Blask DE, Brown GM, et al. Prospects of the clinical utilization of melatonin. Biol Signals Recept 1998; 7: 195-219.
86. Kossoy G, Ben-Hur H, Popovich I, et al. Melatonin and colon carcinogenesis. IV. Effect of melatonin on proliferative activity and expression of apoptosis-related proteins in the spleen of rats exposed to 1,2-dimethylhydrazine. Oncol Rep 2000; 7: 1401-1405.
87. Neri B, de Leonardis V, Gemelli MT, et al. Melatonin as biological response modifier in cancer patients. Anticancer Res 1998; 18: 1329-1332.
88. Bhat TA, Singh RP,. Tumor angiogenesis-a potential target in cancer chemoprevention. Food Chem Toxicol 2008; 46: 1334-1345.
89. Baharara J, Namvar F, Mousavi M, et al. Anti-angiogenesis effect of biogenic silver nanoparticles synthesized using saliva officinalis on chick chorioalantoic membrane (CAM). Molecules 2014; 19: 13498-13508.
90. Prevete N, Liotti F, Visciano C, et al. The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis. Oncogene 2014; doi: 10.1038/onc.2014.309. [Epub ahead of print]
91. Motilva V, Garcia-Maurino S, Talero E, et al. New paradigms in chronic intestinal inflammation and colon cancer: role of melatonin. J Pineal Res 2011; 51: 44-60.
92. Gelfand MV, Hagan N, Tata A, et al. Neuropilin-1 functions as a VEGFR2 co-receptor to guide developmental angiogenesis independent of ligand binding. Elife 2014; 3: e03720.
93. Abusnina A, Keravis T, Zhou Q, et al. Tumour growth inhibition and anti-angiogenic effects using curcumin correspond to combined PDE2 and PDE4 inhibition. Thromb Haemost 2014; 113: 319-328.
94. Lissoni P, Rovelli F, Malugani F, et al. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuro Endocrinol Lett 2001; 22: 45-47.
95. Park SY, Jang WJ, Yi EY, et al. Melatonin suppresses tumor angiogenesis by inhibiting HIF-1alpha stabilization under hypoxia. J Pineal Res 2010; 48: 178-184.
96. Abdel-Gawad IA, Hassanein HM, Bahgat NA, et al. Study of endothelin-1 and vascular endothelial growth factor in patients with cancer colon. J Egypt Natl Canc Inst 2008; 20: 216-223.
97. Orendas P, Kubatka P, Bojkova B, et al. Melatonin potentiates the anti-tumour effect of pravastatin in rat mammary gland carcinoma model. Int J Exp Pathol 2014; 95: 401-410.
98. Reiter RJ, Tan DX, Sainz RM, et al. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 2002; 54: 1299-1321.
99. Martinez Mdel C, Afonso SG, Buzaleh AM, et al. Protective action of antioxidants on hepatic damage induced by griseofulvin. ScientificWorldJournal 2014; 2014: 982358.
100. Cerea G, Vaghi M, Ardizzoia A, et al. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res 2003; 23: 1951-1954.
101. Kontek R, Nowicka H,. The modulatory effect of melatonin on genotoxicity of irinotecan in healthy human lymphocytes and cancer cells. Drug Chem Toxicol 2013; 36: 335-342.
102. Granzotto M, Rapozzi V, Decorti G, et al. Effects of melatonin on doxorubicin cytotoxicity in sensitive and pleiotropically resistant tumor cells. J Pineal Res 2001; 31: 206-213.
103. Lissoni P, Barni S, Mandala M, et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 1999; 35: 1688-1692.
104. Dubocovich ML, Delagrange P, Krause DN, et al. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 2010; 62: 343-380.
105. Tomas-Zapico C, Boga J, Caballero B, et al. Coexpression of MT1 and RORalpha1 melatonin receptors in the Syrian hamster Harderian gland. J Pineal Res 2005; 39: 21-26.
106. Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, et al. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol 2012; 351: 152-166.
107. Karasek M, Pawlikowski M,. Antiproliferative effects of melatonin and CGP 52608. Biol Signals Recept 1999; 8: 75-78.
108. Winczyk K, Pawlikowski M, Karasek M,. Melatonin and RZR/ROR receptor ligand CGP 52608 induce apoptosis in the murine colonic cancer. J Pineal Res 2001; 31: 179-182.
109. Winczyk K, Pawlikowski M, Lawnicka H, et al. Effects of melatonin and melatonin receptors ligand N-[(4-methoxy-1H-indol-2-yl)methyl]propanamide on murine Colon 38 cancer growth in vitro and in vivo. Neuro Endocrinol Lett 2002; 23 (Suppl. 1): 50-54.
110. Winczyk K, Fuss-Chmielewska J, Lawnicka H, et al. Luzindole but not 4-phenyl-2- propionamidotetralin (4P-PDOT) diminishes the inhibitory effect of melatonin on murine Colon 38 cancer growth in vitro. Neuro Endocrinol Lett 2009; 30: 657-662.
111. Di Bella G, Madarena M,. Complete objective response of oesophageal squamocellular carcinoma to biological treatment. Neuro Endocrinol Lett 2009; 30: 312-321.
112. Pereira Rde S,. Regression of gastroesophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and aminoacids: comparison with omeprazole. J Pineal Res 2006; 41: 195-200.
113. Patrick L,. Gastroesophageal reflux disease (GERD): a review of conventional and alternative treatments. Altern Med Rev 2011; 16: 116-133.
114. Madalinski MH,. Does a melatonin supplement alter the course of gastro-esophageal reflux disease? World J Gastrointest Pharmacol Ther 2011; 2: 50-51.
115. Brzozowska I, Strzalka M, Drozdowicz D, et al. Mechanisms of esophageal protection, gastroprotection and ulcer healing by melatonin. Implications for the therapeutic use of melatonin in gastroesophageal reflux disease (GERD) and peptic ulcer disease. Curr Pharm Des 2014; 20: 4807-4815.
116. Kandil TS, Mousa AA, El-Gendy AA, et al. The potential therapeutic effect of melatonin in Gastro-Esophageal Reflux Disease. BMC Gastroenterol 2010; 10: 7.
117. Tan J, Wang Y, Xia Y, et al. Melatonin protects the esophageal epithelial barrier by suppressing the transcription, expression and activity of myosin light chain kinase through ERK1/2 signal transduction. Cell Physiol Biochem 2014; 34: 2117-2127.
118. Proietti S, Cucina A, Reiter RJ, et al. Molecular mechanisms of melatonin's inhibitory actions on breast cancers. Cell Mol Life Sci 2013; 70: 2139-2157.
119. Jung-Hynes B, Schmit TL, Reagan-Shaw SR, et al. Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J Pineal Res 2011; 50: 140-149.
120. Carbajo-Pescador S, Steinmetz C, Kashyap A, et al. Melatonin induces transcriptional regulation of Bim by FoxO3a in HepG2 cells. Br J Cancer 2013; 108: 442-449.
121. Sanchez-Barcelo EJ, Mediavilla MD, Tan DX, et al. Clinical uses of melatonin: evaluation of human trials. Curr Med Chem 2010; 17: 2070-2095.
122. Anisimov VN, Kvetnoy IM, Chumakova NK, et al. Melatonin and colon carcinogenesis. II. Intestinal melatonin-containing cells and serum melatonin level in rats with 1,2-dimethylhydrazine-induced colon tumors. Exp Toxicol Pathol 1999; 51: 47-52.
123. Kvetnaia TV,. Melatonin for diagnosis of cancer and assessment of prognosis in elderly patients. Adv Gerontol 2003; 12: 132-142.
124. Kvetnoi IM, Levin IM,. Daily excretion of melatonin in patients with cancer of the stomach and large intestine. Vopr Onkol 1987; 33: 29-32.
125. Khoory R, Stemme D,. Plasma melatonin levels in patients suffering from colorectal carcinoma. J Pineal Res 1988; 5: 251-258.
126. Kos-Kudla B, Ostrowska Z, Kozlowski A, et al. Circadian rhythm of melatonin in patients with colorectal carcinoma. Neuro Endocrinol Lett 2002; 23: 239-242.
127. Gonzalez-Puga C, Garcia-Navarro A, Escames G, et al. Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin. J Pineal Res 2005; 39: 243-250.
128. Lissoni P, Barni S, Tancini G, et al. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 1994; 69: 196-199.